Answers are grounded in this paper and cite their sources.
Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.
No takes yet. Share an insight, caveat, or question.
Lupo et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: